Abstract:Bladder cancer is the most common malignant tumour in the urinary tract. Approximately 75% of the cases are non-muscle-invasive cancers that can be treated with transurethral resection of the bladder (TURB). One fourth of the patients present with muscle-invasive tumours and require radical cystectomy, occasionally in combination with chemotherapy. In stage T1 bladder cancer, the tumour is not muscle-invasive but has invaded the basal membrane and thus has a high potential to progress to muscle-invasive cancer. In these cases, a secondlook resection should follow the primary TURB to ensure that all tumour tissue has been removed. Intravesical treatment with bacillus Calmette-Guérin (BCG) is recommended to prevent recurrence. Despite existing prognostic models based on clinical and morphological factors, especially in stage T1 bladder cancer, it is difficult to make correct assumptions regarding prognosis and optimal treatment. The aim of the research underlying this thesis was to elucidate various aspects of diagnosis and treatment of stage T1 bladder cancer. The first study used tumours from a previously investigated cohort of 237 patients with bladder cancer of all stages that had previously been classified into five molecular subtypes (urobasal A and B, genomically unstable, squamous carcinoma cell like, and infiltrated), to develop a classifier based on immunohistochemistry (IHC). This IHC classifier could reproduce the molecular subtypes in 88% of the cases. The subtypes were shown to have different biological properties and varying potential to progress. In the second study, this IHC classifier was used to subtype primary stage T1 bladder cancer tumours in a population-based cohort of 167 patients. The risk of progression to muscle-invasive disease depended on the molecular pathological subtype. Outcome was even more precisely predicted by using the molecular pathological subtype in combination with clinical factors or with information on immune response. In the third study, the use of second-look resection was investigated in a population-based cohort including all 910 patients diagnosed with stage T1 bladder cancer in Sweden in 20082009, and the results revealed substantial differences in the use of this procedure in the six healthcare regions. Bladder cancer death was more common in patients with than in those without remaining T1 tumour in their second-look specimens, but was noted even more often in patients that did not undergo second-look resection. Differences in bladder cancer death between healthcare regions could not be explained solely by the observed disparities in the use of second-look resection. The fourth investigation included all 3,758 patients diagnosed with stage T1 bladder cancer in Sweden in 1997-2006. The use of BCG during the study period increased from 18% in 1997-2000 to 31% in 2004-2006. Patients younger than 75 years, patients treated at high-volume hospitals, patients with grade 3 tumours, and patients from the northern, southern, and Uppsala/Örebro healthcare regions were more frequently treated with BCG. Rates of overall and cancer-specific survival were higher in patients treated with BCG and lower in patients that were ≥75 years of age and those with grade 3 tumours. From a population-based perspective, BCG was found to be underused in Sweden, especially in patients aged ≥75 years and those treated at low-volume hospitals.

Preparation and Quality Control of Ketoprofen Binary Ethosomal Gels

Evaluation of the in vitro human skin percutaneous absorption of ketoprofen in topical anhydrous and aqueous gels

Microemulsion-Based Polymer Gels with Ketoprofen and Menthol: Physicochemical Properties and Drug Release Studies

Preparation of ketoprofen cataplasm and research on its skin penetration in vitro

Formulation and evaluation of microemulsion containing ketoprofen

Functionalized multiwalled carbon nanotube-ethosomes for transdermal delivery of ketoprofen: Ex vivo and in vivo evaluation

Characterization of new topical ketoprofen formulations prepared by drug entrapment in solid lipid matrices

[Preparation of Paeonol Microemulsion Gel Its and Transdermal Characterization in Vitro].

Development and characterization of topical ethosomal gel for improved antifungal therapeutics

Designed Fabrication of Phloretin-Loaded Propylene Glycol Binary Ethosomes: Stability, Skin Permeability and Antioxidant Activity

A poly-δ-decalactone (PDL) based nanoemulgel for topical delivery of ketoconazole and eugenol against Candida albicans

Perspective Impact of Gelling Agents on the Mechanistic Behavior for the Topical Delivery of Flufenamic Acid Nano-Ethosomal Dispersion

Quality by Design (QbD) Approach to Develop Colon-Specific Ketoprofen Hot-Melt Extruded Pellets: Impact of Eudragit® S 100 Coating on the In Vitro Drug Release

Preparation of microspheres with sustained ketoprofen release by electrospray for the treatment of aseptic inflammation

Stage T 1 Bladder Cancer – Aspects of Diagnosis and Treatment

Quality by Design Assisted Optimization and Risk Assessment of Black Cohosh Loaded Ethosomal Gel for Menopause: Investigating Different Formulation and Process Variables

Preparation and Evaluation of Hot-Melt Extruded Patient-Centric Ketoprofen Mini-Tablets

Evaluation of Emulgel and Nanostructured Lipid Carrier-Based Gel Formulations for Transdermal Administration of Ibuprofen: Characterization, Mechanical Properties, and Ex-Vivo Skin Permeation

Involvement of Endocytosis in the Transdermal Penetration Mechanism of Ketoprofen Nanoparticles

Ethosome as a potential transdermal drug delivery system

Formulation development of novel in situ nanoemulgel (NEG) of ketoprofen for the treatment of periodontitis